A new low-impact oral weight-loss pill called CX11 has demonstrated significant and steady weight reduction in US patients, with fewer side effects than many existing injectable treatments. The drug now moves forward to its first North American Phase 3 trial, aiming to offer an effective and convenient option for people living with obesity.
- Users lost up to 11.5% body weight over 36 weeks
- Low gastrointestinal side effects, with half the vomiting rates of injectable rivals
- Phase 3 trials underway in North America and China for potential approval
What happened
Corxel's oral GLP-1 receptor agonist, CX11, successfully completed a Phase 2 clinical trial in the United States, enrolling 246 adults with obesity or excess weight along with at least one related health condition. Participants received varying doses of CX11 or a placebo daily for 36 weeks. Those on CX11 experienced consistent and sustained weight loss, up to 11.5% of their baseline body weight, without evidence of the effects plateauing toward the study's end.
Why it feels good
CX11 represents a potential leap forward in obesity treatment because it delivers the benefits of GLP-1 receptor agonists — proven to reduce appetite and body weight — in a convenient, once-daily oral pill form. Unlike current GLP-1 therapies that require injections and cold storage, CX11 can be taken without food restrictions or refrigeration, which simplifies use and access for many patients.
Moreover, its low side effect profile makes the drug more tolerable for users who often struggle with the nausea and vomiting associated with other GLP-1 medications. This means people may be more likely to continue treatment and achieve sustained weight loss, improving their overall health and quality of life. The oral pill approach also helps address supply chain and cost challenges commonly linked to injectable formulations.
What to enjoy or watch next
Corxel is also advancing other cardiometabolic treatments in its pipeline, including CX12, an amylin receptor agonist currently in pre-clinical development. Overall, this progress suggests a growing landscape of innovative oral medications that could transform the way obesity and related conditions are managed worldwide.